MX2023005747A - Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos. - Google Patents

Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos.

Info

Publication number
MX2023005747A
MX2023005747A MX2023005747A MX2023005747A MX2023005747A MX 2023005747 A MX2023005747 A MX 2023005747A MX 2023005747 A MX2023005747 A MX 2023005747A MX 2023005747 A MX2023005747 A MX 2023005747A MX 2023005747 A MX2023005747 A MX 2023005747A
Authority
MX
Mexico
Prior art keywords
gcn2
methods
kinase inhibitors
perk
perk kinase
Prior art date
Application number
MX2023005747A
Other languages
English (en)
Inventor
Patrick Kearney
Daniel L Flynn
Bourdonnec Bertrand Le
Yu Mi Ahn
Jeffery Zwicker
Gada Al-Ani
Salim Javed
Kristen Stoltz
Original Assignee
Deciphera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals Llc filed Critical Deciphera Pharmaceuticals Llc
Publication of MX2023005747A publication Critical patent/MX2023005747A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos que son inhibidores de una GCN2 quinasa o de una PERK quinasa, y métodos de tratamiento con dichos compuestos de enfermedades que incluyen enfermedades asociadas a una GCN2 quinasa o a una PERK quinasa.
MX2023005747A 2020-11-18 2021-11-17 Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos. MX2023005747A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063115496P 2020-11-18 2020-11-18
US202163185846P 2021-05-07 2021-05-07
PCT/US2021/059678 WO2022109001A1 (en) 2020-11-18 2021-11-17 Gcn2 and perk kinase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2023005747A true MX2023005747A (es) 2023-07-28

Family

ID=78844846

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005747A MX2023005747A (es) 2020-11-18 2021-11-17 Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos.

Country Status (14)

Country Link
US (1) US11912668B2 (es)
EP (1) EP4247795A1 (es)
JP (1) JP2023549540A (es)
KR (1) KR20230121758A (es)
AU (1) AU2021381949A1 (es)
BR (1) BR112023009531A2 (es)
CA (1) CA3198943A1 (es)
CL (1) CL2023001399A1 (es)
CO (1) CO2023006705A2 (es)
IL (1) IL302807A (es)
MX (1) MX2023005747A (es)
PE (1) PE20231311A1 (es)
TW (1) TW202237568A (es)
WO (1) WO2022109001A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202008749D0 (en) 2020-06-09 2020-07-22 Ip2Ipo Innovations Ltd Novel compounds
JP2023549540A (ja) 2020-11-18 2023-11-27 デシフェラ・ファーマシューティカルズ，エルエルシー Ｇｃｎ２およびｐｅｒｋキナーゼ阻害剤およびその使用方法
CA3229293A1 (en) * 2021-09-10 2023-03-16 Pui Yee Ng 6-aza-quinoline derivatives and related uses
WO2023102228A1 (en) * 2021-12-03 2023-06-08 Deciphera Pharmaceuticals, Llc Heterocyclic compopunds as gcn2 and perk kinase inhibitors
WO2023159322A1 (en) * 2022-02-25 2023-08-31 Ontario Institute For Cancer Research (Oicr) Quinazoline derivatives as inhibitors of the gcn2 kinase, compositions and uses thereof
WO2023196659A1 (en) * 2022-04-08 2023-10-12 Alesta Therapeutics BV Gcn2 modulator compounds
WO2023218195A1 (en) * 2022-05-11 2023-11-16 Ip2Ipo Innovations Limited Gcn2 inhibitorr
WO2023239165A1 (ko) * 2022-06-08 2023-12-14 한국화학연구원 페닐설폰아마이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2024081916A1 (en) * 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4038932A1 (de) 1990-12-06 1992-06-11 Roehm Gmbh Diuretische und antikaliuretisch wirksame pteridinderivate
US6060477A (en) 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
AU748884B2 (en) 1997-03-19 2002-06-13 Abbott Gmbh & Co. Kg Pyrrolo(2,3d)pyrimidines and their use as tyrosine kinase inhibitors
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
AU752474B2 (en) 1998-09-18 2002-09-19 Abbott Gmbh & Co. Kg 4-aminopyrrolopyrimidines as kinase inhibitors
US7276506B2 (en) 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
PL354249A1 (en) 1999-09-17 2003-12-29 Abbott Gmbhabbott Gmbh Pyrazolopyrimidines as therapeutic agents
WO2001072751A1 (en) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
US20030225098A1 (en) 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
US20030199525A1 (en) 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US20050008640A1 (en) 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
JP2006528685A (ja) 2003-05-06 2006-12-21 スミスクライン ビーチャム コーポレーション 新規化合物
US20050026944A1 (en) 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
US7202363B2 (en) 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
CA2534549A1 (en) 2003-09-12 2005-03-24 4 Aza Bioscience Nv Pteridine derivatives for the treatment of septic shock and tnf-.alpha.-related diseases.
AU2004279427B2 (en) 2003-10-08 2008-07-03 Irm Llc Compounds and compositions as protein kinase inhibitors
KR20060123452A (ko) 2003-12-09 2006-12-01 버텍스 파마슈티칼스 인코포레이티드 나프티리딘 유도체 및 무스카린 수용체의 조절자로서의이의 용도
CA2549641A1 (en) 2003-12-19 2005-07-21 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2553724A1 (en) 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
JP2008504281A (ja) 2004-06-23 2008-02-14 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
EP1835934A4 (en) 2004-12-23 2010-07-28 Deciphera Pharmaceuticals Llc ENZYME MODULATORS AND TREATMENTS
RU2007138264A (ru) 2005-03-17 2009-09-10 Новартис АГ (CH) N-[3-(1-АМИНО-5,6,7,8-ТЕТРАГИДРО-2,4,4b-ТРИАЗАФЛУОРЕН-9-ИЛ)ФЕНИЛ]БЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИН/ТРЕОНИНКИНАЗ, ПРЕЖДЕ ВСЕГО КИНАЗ В-RAF
US20090318456A1 (en) 2006-07-06 2009-12-24 Gilead Sciences, Inc. Substituted pteridines for the treatment and prevention of viral infections
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EA016388B1 (ru) 2006-09-15 2012-04-30 Пфайзер Продактс Инк. Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
US7893066B2 (en) 2006-10-05 2011-02-22 Gilead Palo Alto, Inc. Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
KR20090057416A (ko) 2006-10-05 2009-06-05 씨브이 쎄러퓨틱스, 인코포레이티드 스테아로일 ＣｏＡ 탈포화효소 억제제로서 사용하기 위한, 바이시클릭 질소 함유 헤테로시클릭 화합물
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
WO2008051757A1 (en) 2006-10-20 2008-05-02 Irm Llc Compositions and methods for modulating c-kit and pdgfr receptors
WO2008077649A1 (en) 2006-12-26 2008-07-03 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infectons
JP2010523653A (ja) 2007-04-09 2010-07-15 ギリアード・パロ・アルト・インコーポレイテッド ステアロイルＣｏＡデサチュラーゼのインヒビターとして使用するためのプテリジノン誘導体
AU2008242697A1 (en) 2007-04-20 2008-10-30 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
EP2265270A1 (en) 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
EP2262796A1 (en) 2008-03-04 2010-12-22 Vitae Pharmaceuticals, Inc. Aurora kinase inhibitors
CA2719650A1 (en) 2008-04-10 2009-10-15 Gilead Sciences, Inc. Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
US8536187B2 (en) 2008-07-03 2013-09-17 Gilead Sciences, Inc. 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections
UY31984A (es) 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas.
UY31982A (es) 2008-07-16 2010-02-26 Boehringer Ingelheim Int Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
AU2009308853A1 (en) 2008-10-29 2010-05-06 Deciphera Pharmaceuticals, Llc Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
US9765037B2 (en) 2010-01-28 2017-09-19 University Of Washington Through Its Center For Commercialization Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
AU2011245248B2 (en) 2010-04-29 2016-01-07 Deciphera Pharmaceuticals, Llc Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activites
CA2800998A1 (en) 2010-04-29 2011-11-10 Deciphera Pharmaceuticals, Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
JP2014501261A (ja) 2010-12-23 2014-01-20 アムジエン・インコーポレーテツド 複素環化合物およびそれらの使用
WO2013043232A2 (en) 2011-04-08 2013-03-28 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido [2,3-d]pyrimidin-7(8h) -ones for the treatment of nervous system disorders and cancer
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
AU2012100477A4 (en) 2011-08-26 2012-06-14 Paul Alan Alessi Improvements relating to brush harvesters
MX2014005292A (es) 2011-11-04 2014-09-11 Afraxis Holdings Inc Inhibidores de pak para el tratamiento de síndrome del x frágil.
JP2015507606A (ja) 2011-11-22 2015-03-12 デシフェラ ファーマシューティカルズ，エルエルシー 抗癌および抗増殖作用を示すピリドンアミドおよび類似体
WO2013134298A1 (en) 2012-03-07 2013-09-12 Deciphera Pharmaceuticals, Llc Raf inhibitor compounds
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
AU2013277582B2 (en) 2012-06-18 2017-11-30 Principia Biopharma Inc. Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases
CN102746241B (zh) 2012-07-02 2014-11-05 西安交通大学 2,3,5-三取代苯甲酰胺类化合物及其制备方法和用途
US20140038991A1 (en) 2012-08-06 2014-02-06 Astar Biotech Llc Protein Kinase Inhibitors
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
WO2014043296A1 (en) 2012-09-14 2014-03-20 Eternity Bioscience Inc. Aminoisoquinoline derivatives as protein kinase inhibitors
US9193719B2 (en) 2013-03-15 2015-11-24 Deciphera Pharmaceuticals, Llc 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities
ES2817902T3 (es) 2013-03-15 2021-04-08 Deciphera Pharmaceuticals Llc N-acil-N'-(piridin-2-il) ureas y análogos que presentan actividades anticancerosas y antiproliferativas
WO2014145029A2 (en) 2013-03-15 2014-09-18 Deciphera Pharmaceuticals, Llc N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
EP2970300B1 (en) 2013-03-15 2018-05-16 Boehringer Ingelheim International GmbH Heteroaromatic compounds as btk inhibitors
US9012635B2 (en) 2013-03-15 2015-04-21 Deciphera Pharmaceuticals, Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
WO2014145025A2 (en) 2013-03-15 2014-09-18 Deciphera Pharmaceuticals, Llc 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities
US9133183B2 (en) 2013-03-15 2015-09-15 Deciphera Pharmaceuticals, Llc Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities
US9457019B2 (en) 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
CN105330699B (zh) 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
CN105481858B (zh) 2014-10-11 2019-05-17 上海医药集团股份有限公司 一种含氮稠杂环化合物、其制备方法、组合物及应用
CN105968108B (zh) 2016-05-12 2017-07-04 淮海工学院 一种合成帕布昔利布中间体的方法
FI3472165T3 (fi) 2016-06-21 2023-12-11 Nerviano Medical Sciences Srl N-(substituoidun fenyyli-)sulfoniamidin johdannaiset kinaasi-inhibiittoreina
JP6726773B2 (ja) 2016-07-07 2020-07-22 デウン ファーマシューティカル カンパニー リミテッド 新規な４−アミノピラゾロ［３，４−ｄ］ピリミジニルアザビシクロ誘導体およびこれを含む薬学組成物
WO2018046739A1 (de) 2016-09-12 2018-03-15 Covestro Deutschland Ag Pulverbasiertes additives fertigungsverfahren bei niedriger temperatur
JP6919922B2 (ja) 2016-12-19 2021-08-18 アビスコ セラピューティクス カンパニー リミテッド Ｆｇｆｒ４阻害剤、その製造方法と薬学的な応用
CA3174890A1 (en) 2016-12-26 2018-07-05 Institute Of Materia Medica, Chinese Academy Of Medical Sciences Quinazoline compound and its use as a phosphatidylinositol 3-kinase (pi3k) inhibitor
AU2018226315B2 (en) 2017-02-27 2021-01-28 Betta Pharmaceuticals Co., Ltd. FGFR inhibitor and application thereof
WO2018222173A1 (en) 2017-05-30 2018-12-06 Deciphera Pharmaceuticals, Inc. Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha
JP7126084B2 (ja) 2017-06-01 2022-08-26 コーネル ユニバーシティー Ｉｒｅ１小分子阻害薬
CA3066979A1 (en) 2017-06-13 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as h-pgds inhibitors
CN109721531B (zh) 2017-10-27 2022-07-29 中国科学院合肥物质科学研究院 一种新型的脂质体激酶抑制剂
CN111566089B (zh) 2017-11-10 2023-11-17 康奈尔大学 Ire1小分子抑制剂
EA202091761A1 (ru) 2018-01-31 2020-12-14 ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Комбинированная терапия для лечения гастроинтестинальных стромальных опухолей
EP3746060A1 (en) 2018-01-31 2020-12-09 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of mastocytosis
US20210261544A1 (en) 2018-09-14 2021-08-26 Abbisko Therapeutics Co., Ltd. Fgfr inhibitor, preparation method therefor and application thereof
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
CA3121755A1 (en) 2018-12-03 2020-06-11 Cornell University Ire1 small molecule inhibitors
KR20210119411A (ko) 2018-12-28 2021-10-05 데시페라 파마슈티칼스, 엘엘씨. 암 치료에 사용하기 위한 csf1r 억제제
WO2020142612A1 (en) 2019-01-03 2020-07-09 Genentech, Inc. Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases.
WO2020147097A1 (zh) 2019-01-18 2020-07-23 中国科学院合肥物质科学研究院 一种新型的脂质体激酶抑制剂
TWI756636B (zh) 2019-02-18 2022-03-01 美商建南德克公司 嘧啶并嘧啶化合物及使用方法
KR20200100429A (ko) 2019-02-18 2020-08-26 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 신규한 피리도[3,4-d]피리미딘-8-온 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
WO2020177729A1 (zh) 2019-03-06 2020-09-10 江苏恒瑞医药股份有限公司 稠合芳香环类衍生物、其制备方法及其在医药上的应用
WO2020210828A1 (en) 2019-04-12 2020-10-15 Hibercell, Inc. (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions
FI3966206T3 (fi) 2019-05-10 2023-10-20 Deciphera Pharmaceuticals Llc Heteroaryyliaminopyrimidiiniamidi-autofagiaestäjiä ja niiden käyttömenetelmiä
LT3966207T (lt) 2019-05-10 2023-12-11 Deciphera Pharmaceuticals, Llc Fenilaminopirimidino amidai, kaip autofagijos inhibitoriai ir jų panaudojimo būdai
US20220227730A1 (en) 2019-05-15 2022-07-21 Cornell University Treatment of fibrosis with ire1 small molecule inhibitors
WO2020232401A1 (en) 2019-05-15 2020-11-19 Cornell University Combination therapies with ire1 small molecule inhibitors
JOP20210317A1 (ar) 2019-05-31 2023-01-30 Servier Lab مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان
CN114302877A (zh) 2019-06-11 2022-04-08 基因泰克公司 喹唑啉基化合物及使用方法
WO2020257180A1 (en) 2019-06-17 2020-12-24 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
AU2020329956B2 (en) 2019-08-12 2023-11-16 Deciphera Pharmaceuticals, Llc. Ripretinib for treating gastrointestinal stromal tumors
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
US20230277522A9 (en) 2019-08-12 2023-09-07 Deciphera Pharmaceuticals, Llc Methods for treating vascular malformations
AU2020417282B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
HRP20231699T1 (hr) 2019-12-30 2024-05-10 Deciphera Pharmaceuticals, Llc Formulacije inhibitora amorfne kinaze i postupci njihove primjene
KR102396930B1 (ko) 2020-01-15 2022-05-12 한국과학기술연구원 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물
AU2021222818A1 (en) * 2020-02-17 2022-09-01 Alesta Therapeutics BV GCN2 modulator compounds
JP2023549540A (ja) 2020-11-18 2023-11-27 デシフェラ・ファーマシューティカルズ，エルエルシー Ｇｃｎ２およびｐｅｒｋキナーゼ阻害剤およびその使用方法
EP4251165A1 (en) 2020-11-25 2023-10-04 Deciphera Pharmaceuticals, LLC Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection
US20220193083A1 (en) 2020-11-25 2022-06-23 Deciphera Pharmaceuticals, Llc Anti-viral activity of vps34 inhibitors
CN117241800A (zh) 2020-11-25 2023-12-15 德西费拉制药有限责任公司 Vps34抑制剂的抗病毒活性
CN117136062A (zh) 2020-11-25 2023-11-28 德西费拉制药有限责任公司 Vps34抑制剂的抗病毒活性
JP2023553810A (ja) 2020-11-25 2023-12-26 デシフェラ・ファーマシューティカルズ，エルエルシー Ｖｐｓ３４阻害剤の抗ウイルス活性
WO2022115545A1 (en) 2020-11-25 2022-06-02 Deciphera Pharmaceuticals, Llc Pyridylpyridone derivatives as vsp34 inhibitors for use in the treatment of a viral infection

Also Published As

Publication number Publication date
US20220274934A1 (en) 2022-09-01
PE20231311A1 (es) 2023-08-24
AU2021381949A1 (en) 2023-06-15
CL2023001399A1 (es) 2023-12-15
US11912668B2 (en) 2024-02-27
IL302807A (en) 2023-07-01
JP2023549540A (ja) 2023-11-27
CO2023006705A2 (es) 2023-09-29
BR112023009531A2 (pt) 2023-10-03
TW202237568A (zh) 2022-10-01
CA3198943A1 (en) 2022-05-27
WO2022109001A1 (en) 2022-05-27
KR20230121758A (ko) 2023-08-21
EP4247795A1 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
MX2023005747A (es) Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos.
MX2021008342A (es) Derivados de pirazol como inhibidores de calicreina plasmatica.
MX2022002465A (es) Inhibidores de kras g12d.
JOP20190186A1 (ar) مركب كينازولين
MX2020006128A (es) Inhibidores de la proteina de activacion de fibroblastos.
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
AU2017382297A8 (en) Phosphodiesterase inhibitors and methods of microbial treatment
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
AU2018329925A8 (en) Diagnostic and therapeutic methods for cancer
MX2019002108A (es) Terapia de combinacion con inhibidores de glutaminasa.
MX2022001004A (es) Inhibidores de enzimas.
WO2020021477A3 (en) Compositions and methods for treating the eye
AU2019310335A8 (en) Methods of treating cancer with PI3K inhibitor, GDC-0077
MX2018015172A (es) Metodos para tratar cancer pancreatico.
MX2023001236A (es) Inhibidores de cinasa inducibles por sal.
JOP20220107A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
MX2019013862A (es) Terapia de combinacion.
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
MX2023007793A (es) Compuestos de indazol como inhibidores de cinasas.
CR20220280A (es) Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
MX2022000811A (es) Inhibidores de enzimas.
ZA202106519B (en) Caspase inhibitors and methods of use thereof